Pregnancy in epileptic patients: comparison between well-established therapeutic strategies and opportunities coming from new drugs

Francesca Pizzo, Arianna Dilaghi, Anna Maria Romoli, Silvia Pradella, Andrea La Licata, Barbara Chiocchetti, Alessandra Pistelli, Marco Paganini

DOI: https://doi.org/10.7175/cmi.v7i3.890

Abstract

Treating women affected by epilepsy during pregnancy is challenging.  Clinicians have to consider both the teratogenic effects of Antiepileptic Drugs (AEDs) and the risk of seizure recurrence. Pharmacokinetic changes during pregnancy are rapid and conspicuous so that the serum concentration of drugs can be modified and the effectiveness of AEDs cannot be guaranteed. The aim of this study is to evaluate the risk of Major Congenital Malformation (MCM) associated with AEDs treatment during the first trimester of pregnancy. We collected data from 338 patients who contacted the Teratology Information Services of XXX University Hospital and we found that only the variable monotherapy vs politherapy had statistical significance for MCM. More studies are needed to assess the efficacy and safety of newer AEDs.

Keywords

Epilepsy; Pregnancy; Antiepileptic Drugs; Teratogenic Effects

Full Text

HTML PDF

References

  • Koren G. Pharmacokinetics in pregnancy; Clinical Significance. Presentato a “Clinically relevant pharmacokinetic changes in pregnancy”, May 27, 2011, Montréal, Quebec
  • Regione Toscana. RTDC. Registro Toscano Difetti Congeniti. http://www.rtdc.it/registro_malformazioni.htm (ultimo accesso dicembre 2013)
  • Carter CO. Genetics of common single malformations. Br Med Bull 1976; 32: 21-6
  • Fraser FC. The multifactorial/threshold concept – uses and misuses. Teratology 1976; 14: 267-801. 267-801; http://dx.doi.org/10.1002/tera.1420140302
  • Brent RL. Environmental causes of human congenital malformations. Pediatrics 2004; 113: 957-68
  • Batagol R. Australian Drug Evaluation Committee: Medicines in pregnancy-An Australian categorisation of risk of drug use in pregnancy, 4th. Australian Government Publishing Service, Canberra, Australia, 1999
  • Czeizel AE, Timar L, Sarkozi A. Dose-dependent effect of folic acid on the prevention of orofacial clefts. Pediatrics 1999; 104: e66; http://dx.doi.org/10.1542/peds.104.6.e66
  • Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. Am J Med Genet 2004; 125C: 12-21; http://dx.doi.org/10.1002/ajmg.c.30004
  • Wald NJ, Law MR, Morris JK, et al. Quantifying the effect of folic acid. Lancet 2001; 358: 2069-73; http://dx.doi.org/10.1016/S0140-6736(01)07104-5
  • Forsgren L, Beghi E, Oun A, et al. The epidemiology of epilepsy in Europe – a systematic review. Eur J Neurol 2005; 12: 245-53; http://dx.doi.org/10.1111/j.1468-1331.2004.00992.x
  • Tomson T, Battino D. Teratogenic effects of antiepileptic medications. Neurol Clin 2009; 27: 993-1002; http://dx.doi.org/10.1016/j.ncl.2009.06.006
  • EURAP Study Group. Seizure control and treatment in pregnancy: observation from EURAP epilepsy pregnancy registry. Neurology 2006; 66: 354-60; http://dx.doi.org/10.1212/01.wnl.0000195888.51845.80
  • Teramo K, Hiilesmaa V, Bardy A, et al. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 1979; 7: 3-6; http://dx.doi.org/10.1515/jpme.1979.7.1.3
  • Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005; 4: 781-6; http://dx.doi.org/10.1016/S1474-4422(05)70224-6
  • Jentink J, Loane MA, Dolk H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med 2010; 362; 2185-93; http://dx.doi.org/10.1056/NEJMoa0907328
  • Harden CL, Meador KJ, Pennell PB, et al; American Academy of Neurology; American Epilepsy Society. Practice Parameter update: Management issues for women with epilepsy --Focus on pregnancy (an evidence-based review): Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73: 133-41; http://dx.doi.org/10.1212/WNL.0b013e3181a6b312
  • Shallcross R, Bromley RL, Irwin B, et al; Liverpool Manchester Neurodevelopment Group; UK Epilepsy and Pregnancy Register. Child development following in utero exposure levetiracetam vs sodium valproate. Neurology 2011; 76: 383-9; http://dx.doi.org/10.1212/WNL.0b013e3182088297
  • Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011; 305: 1996-2002; http://dx.doi.org/10.1001/jama.2011.624
  • ISTAT. http://dati.istat.it/?lang=it (ultimo accesso dicembre 2013)
  • Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 2013; 54: 405-14; http://dx.doi.org/10.1111/epi.12109
  • Aguglia U, Barboni G, Battino D, et al. Italian consensus conference on epilepsy and pregnancy, labor and puerperium. Epilepsia 2009; 50 (Suppl 1); 7-23; http://dx.doi.org/10.1111/j.1528-1167.2008.01964.x

Statistics

Abstract: 722 views
HTML: 802 views
PDF: 1741 views

Refbacks

  • There are currently no refbacks.




© SEEd srl